ALZFORUM4d
Tau Modification Drugs Take a Hit with Negative Trial
Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...
ALZFORUM4d
Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...
ALZFORUM4d
Leqembi: Side Effects No Worse in Clinical Use Than They Were in Trial
An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...
ALZFORUM4d
Finally, Therapeutic Antibodies Start to Reduce Tangles
The fifth time may be the charm for antibodies targeting tau. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Brussels-based UCB Pharma ...
ALZFORUM5d
Member Directory
Andre Padure, M.B.A., L.L.B. Toronto, Canada ...
ALZFORUM6d
CONFERENCE CALENDAR
Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected].